A Phase 3 interventional study of Lofexidine HCl and Placebo in Opioid Dependence and Acute Opioid Withdrawal Syndrome, sponsored by USWM, LLC (dba US WorldMeds). Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-22.
Sponsored by USWM, LLC (dba US WorldMeds) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing lofexidine in Opioid-Related Disorders — none open to participants now, 1 under way, none of them phase 3. lofexidine · Opioid-Related Disorders.
Among the 15 studies testing lofexidine in Opioid-Related Disorders, this one has the largest enrollment, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 10th registered.
1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
Browse Opioid-Related Disorders studies →None of the 15 studies testing lofexidine in Opioid-Related Disorders is open now. The open studies under Opioid-Related Disorders, anywhere →
lofexidine: first FDA approval 2018 (LUCEMYRA). What it is approved for, and how studies give it, is on its page →
Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 603 is above the median of 63 across 1,167 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 30 across the 15 interventional studies. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 15 have an industry lead sponsor. The 8 most frequent:
USWM, LLC (dba US WorldMeds) is the lead sponsor of 17 studies on the registry; none are open to participants now.
USWM, LLC (dba US WorldMeds) has 6 studies filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies testing lofexidine in Opioid-Related Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05027919University of Maryland, BaltimoreAssessing a Clinically-meaningful Opioid Withdrawal Phenotype | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing lofexidine in Opioid-Related Disorders, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride, an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids. The study takes place in 2 parts: a 7-day inpatient double-blind treatment portion where subjects will be randomly assigned to one of three doses of study medication (2.4 mg total daily dose of lofexidine, 3.2 mg total daily dose of lofexidine, or placebo) followed by an optional open-label treatment period where subjects will be inpatient or outpatient and receive lofexidine at variable dosing for up to an additional 7 days. The Investigator hypothesizes that subjects will achieve maximum treatment effect with tolerable side effects at the 3.2 mg total daily dose and that both the 3.2 mg and 2.4 total daily doses will show better efficacy over placebo in treating symptoms of acute opioid withdrawal.
This is a Phase 3, two-part, multicenter study to evaluate the dose-response, efficacy, and safety of lofexidine in alleviation of symptoms in subjects undergoing total and abrupt withdrawal from short-acting opioids. Any subject dependent on short-acting opioids (the primary projected indication for lofexidine) about to undergo opioid withdrawal will be eligible. Subjects will be evaluated for their compliance with protocol inclusion/exclusion criteria during a screening period, lasting up to 7 days.
The first part of the study will use an inpatient, randomized, double-blind, and placebo-controlled design (Days 1-7) followed by a second part, an open-label continuation treatment (Days 8-14). A total of 600 subjects will be randomized to receive lofexidine 2.4 mg total daily dose (0.6 mg QID), lofexidine 3.2 mg total daily dose (0.8 mg QID), or matching placebo in a 3:3:2 ratio (225:225:150) for 7 days (i.e., during the most intense stage of withdrawal). During the second part of the study (Days 8-14), all subjects, regardless of their treatment assignment (which will remain double-blinded), who successfully meet the definition for "completer" based on Days 1-7 (i.e., receives at least one dose of study medication on Day 7 and completes the 3.5-hour post-dose SOWS-Gossop assessment on Day 7), will be eligible to receive open-label, variable dose lofexidine treatment (as determined by the Site Investigator, but not to exceed 3.2 mg/day) for up to an additional 7 days in either an inpatient or outpatient setting depending on the wishes of the investigator and the subject. No subject will receive lofexidine for more than 14 days total from the onset of abstinence. There will be no initial dose run-up and no mandated terminal dose taper.
Efficacy and safety assessments will be made daily throughout the study. Safety will be assessed by evaluation of adverse event, clinical labs, electrocardiograms (with special attention to QTc), vital signs, physical exam data, and the Columbia-Suicide Severity Rating Scale. Efficacy will be evaluated daily by subject- and observer-completed scales including the Short Opiate Withdrawal Scale of Gossop (SOWS-G)(the primary outcome measure is SOWS-G score area under the curve for Days 1-7), the Clinical Opiate Withdrawal Scales (COWS), Objective Opiate Withdrawal Scale (OOWS-Handelsman), the Visual Analog Scale for Efficacy (VAS-E), and the Modified Clinical Global Impressions scales for efficacy and side effects. Efficacy will also be evaluated by study retention, completion rates, concomitant medication use, incidence of withdrawal-related Adverse Events (AEs), and subject treatment status 30 days post last dose of study medication. Qualitative urine drug screening will be done every other day to monitor for contraband (inpatient setting) or illicit (outpatient setting) drug use. Upon a subject's exit from the study, Study Discontinuation/End of Study assessments will be done.
During the study, study drug compliance will be documented in the source daily. During the first part of the study (Days 1-7), subjects will be inpatient and each dose of study medication will be administered by study site personnel and recorded in the source. Study medication will be dosed QID at 8 AM, 1 PM, 6 PM and 11 PM. During the second part of the study (Days 8-14), subjects who remain inpatient will be administered each dose of study medication by study site personnel and dosing will be captured in the source. Subjects who complete the second part of the study on an outpatient basis will return to the clinic daily for study assessments. During the open-label period, subjects will be dispensed 1-2 days worth of study drug, as needed to allow for flexibility in scheduling daily visits, to get them through until they are supposed to return the following day for additional study assessments and dosing.
Study medication will be held if vital signs meet any of the following criteria: Resting (sitting or recumbent, if required, for treatment of an adverse event): Systolic blood pressure \<90 mmHg and >20% below screen value; Diastolic blood pressure \<50 mmHg and >20% below screen value; Heart rate \<50 bpm and >20% below screen value; and Symptoms of hypotension and/or bradycardia (e.g., lightheadedness, dizziness, syncope).Orthostatic (after standing for 3 minutes): Systolic blood pressure diastolic blood pressure, or pulse >25% below recumbent values.
A subject will be discontinued from the study if any of the following criteria are met: Systolic blood pressure \<70 mmHg and >20% below screen value; Diastolic blood pressure \<40 mmHg and >20% below screen value; Heart rate \<40 bpm and >20% below screen value; QTc >500 msec or >25% above screen value for both males and females; Syncope; Subject misses more than 2 doses in 24 hours during Days 1-7 prior to meeting "completer" criteria (i.e., receives at least one dose of study medication on Day 7 and completed the 3.5-hour post-dose SOWS-Gossop assessments on Day 7); Subject misses a total of 6 doses during Days 1-7 prior to meeting "completer" criteria (i.e., receives at least one dose of study medication on Day 7 and completed the 3.5-hour post-dose SOWS-Gossop assessments on Day 7); Concomitant medication use (other than alumina, magnesia, and simethicone) for intolerable nausea and emesis.
Subjects should be discontinued from the study for any of the reasons listed below, and the event should be recorded as an Adverse Event (AE) and the subject followed until medically stabilized to the satisfaction of the attending physician: New onset of clinically significant abnormal ECG (e.g., second or third degree heart block or uncontrolled arrhythmia, prolonged QTcF interval); Persistent symptomatic hypotension (e.g., hypotension not responding to bed rest or fluids); Single occurrence of symptomatic bradycardia (as assessed by the Investigator, regardless of blood pressure) associated with chest pain, shortness of breath, or decreased level of consciousness; Persistent hypertension - blood pressure ≥185/110 mmHg recorded on 3 separate occasions taken at least 5 minutes apart AND within a 1-hour time period. If all 3 readings are ≥185/110 mmHg (either systolic ≥185 mmHg or diastolic ≥110 mmHg) the subject must be terminated; Medical Intervention for Cardiovascular Event: Any medical intervention (nonmedication or medication inclusive) used for the treatment of any cardiovascular event, with the exception of a positional intervention in subjects displaying hypotension; Any other clinically significant cardiovascular signs or symptoms that would place the subject at risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.
Drug: Lofexidine HCl · Drug: Placebo
225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.
Drug: Lofexidine HCl
150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.
Drug: Placebo
During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.
Drug: Open Label Lofexidine HCL
Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores
The SOWS-Gossop was completed by the mITT population subject at baseline, once daily at 3.5 hours after the first dose of the study medication on Days 1 to 7. It consists of 10 items that are scored on a 4-point scale; 0=none, 1=mild, 2=moderate, and 3=severe. The overall score is the simple sum of the 10-item scores (minimum overall score of 0, maximum score of 30). Higher individual scores on the scale indicate greater symptom severity. However, as the outcome measure is a difference from placebo, a lower number indicates a better outcome. mITT population: all randomized subjects who received at least 1 dose of study medication
Time frame: Days 1 through 7
Completion Status
The percentage of subjects in each treatment arm who receive at least one dose of study medication on Day 7 and complete the 3.5 hour post-dose SOWS-Gossop assessment on Day 7.
Time frame: Day 7
| Milestone | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | OL: All Lofexidine HCl |
|---|---|---|---|---|
| Started | 229 | 222 | 151 | 0 |
| Completed | 95 | 88 | 42 | 0 |
| Not completed | 134 | 134 | 109 | 0 |
| Milestone | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | OL: All Lofexidine HCl |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 83 |
| Completed | 0 | 0 | 0 | 70 |
| Not completed | 0 | 0 | 0 | 13 |
The SOWS-Gossop was completed by the mITT population subject at baseline, once daily at 3.5 hours after the first dose of the study medication on Days 1 to 7. It consists of 10 items that are scored on a 4-point scale; 0=none, 1=mild, 2=moderate, and 3=severe. The overall score is the simple sum of the 10-item scores (minimum overall score of 0, maximum score of 30). Higher individual scores on the scale indicate greater symptom severity. However, as the outcome measure is a difference from placebo, a lower number indicates a better outcome. mITT population: all randomized subjects who received at least 1 dose of study medication
| score on a scale | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo |
|---|---|---|---|
| Day 1 | 7.8 ± 6.00 | 7.6 ± 6.75 | 9.4 ± 6.81 |
| Day 2 | 10.2 ± 6.83 | 9.9 ± 7.38 | 13.9 ± 8.29 |
| Day 3 | 7.6 ± 5.53 | 7.4 ± 6.34 | 10.9 ± 6.76 |
| Day 4 | 5.7 ± 5.32 | 5.5 ± 5.36 | 9.2 ± 6.81 |
| Day 5 | 4.7 ± 4.60 | 4.5 ± 4.96 | 6.4 ± 5.91 |
| Day 6 | 3.6 ± 3.97 | 3.2 ± 4.10 | 4.4 ± 5.80 |
| Day 7 | 2.7 ± 3.45 | 2.3 ± 3.23 | 2.7 ± 4.60 |
The percentage of subjects in each treatment arm who receive at least one dose of study medication on Day 7 and complete the 3.5 hour post-dose SOWS-Gossop assessment on Day 7.
| Participants | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo |
|---|---|---|---|
| Yes/Complete | 95 | 88 | 42 |
| No/Did Not Complete | 134 | 134 | 109 |
Collected over Through study completion (14 Days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB: Lofexidine HCl 2.4mg Dose | 0/229 (0%) | 0/229 (0%) | 216/229 (94.3%) |
| DB: Lofexidine HCl 3.2mg Dose | 1/222 (0.5%) | 5/222 (2.3%) | 211/222 (95%) |
| DB: Placebo | 0/151 (0%) | 2/151 (1.3%) | 134/151 (88.7%) |
| OL: All Lofexidine HCl | 0/83 (0%) | 0/83 (0%) | 46/83 (55.4%) |
| Event | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | OL: All Lofexidine HCl |
|---|---|---|---|---|
| SyncopeNervous system disorders | 0/229 | 2/222 | 0/151 | 0/83 |
| Acute hepatitis CInfections and infestations | 0/229 | 0/222 | 1/151 | 0/83 |
| Electrocardiogram QT prolongedInvestigations | 0/229 | 0/222 | 1/151 | 0/83 |
| OverdoseInjury, poisoning and procedural complications | 0/229 | 1/222 | 0/151 | 0/83 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/229 | 1/222 | 0/151 | 0/83 |
| Suicidal ideationPsychiatric disorders | 0/229 | 1/222 | 0/151 | 0/83 |
| Event | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | OL: All Lofexidine HCl |
|---|---|---|---|---|
| InsomniaPsychiatric disorders | 117/229 | 123/222 | 73/151 | 4/83 |
| Orthostatic hypotensionVascular disorders | 67/229 | 94/222 | 7/151 | 4/83 |
| BradycardiaCardiac disorders | 54/229 | 70/222 | 8/151 | 3/83 |
| HypotensionVascular disorders | 69/229 | 67/222 | 2/151 | 7/83 |
| PainGeneral disorders | 51/229 | 42/222 | 36/151 | 4/83 |
| DiarrhoeaGastrointestinal disorders | 51/229 | 48/222 | 35/151 | 5/83 |
| DizzinessNervous system disorders | 44/229 | 51/222 | 4/151 | 3/83 |
| NauseaGastrointestinal disorders | 50/229 | 27/222 | 32/151 | 0/83 |
| MyalgiaMusculoskeletal and connective tissue disorders | 30/229 | 22/222 | 25/151 | 1/83 |
| VomitingGastrointestinal disorders | 23/229 | 19/222 | 24/151 | 1/83 |
Demographic Characteristics of modified intent-to-treat "mITT" Population (excludes one subject who randomized but never received study drug)
| Age, Continuous(years) | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | Total |
|---|---|---|---|---|
| Mean | 35 ± 10.8 | 35 ± 10.5 | 36 ± 11.9 | 35 ± 11.0 |
| Sex: Female, Male(Participants) | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | Total |
|---|---|---|---|---|
| Female | 67 | 64 | 44 | 175 |
| Male | 162 | 158 | 107 | 427 |
| Ethnicity (NIH/OMB)(Participants) | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 33 | 28 | 22 | 83 |
| Not Hispanic or Latino | 196 | 194 | 129 | 519 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 | 4 |
| Asian | 1 | 3 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 3 | 5 |
| Black or African American | 54 | 48 | 26 | 128 |
| White | 169 | 158 | 117 | 444 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 9 | 2 | 16 |
| Body weight(kg) | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | Total |
|---|---|---|---|---|
| Mean | 76.0 ± 16.88 | 76.1 ± 16.59 | 76.0 ± 14.94 | 76.1 ± 16.29 |
| BMI (kg/m^2)(kg/m^2) | DB: Lofexidine HCl 2.4mg Dose | DB: Lofexidine HCl 3.2mg Dose | DB: Placebo | Total |
|---|---|---|---|---|
| Mean | 25.1 ± 4.71 | 25.1 ± 5.32 | 25.1 ± 4.63 | 25.1 ± 4.92 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jun 2013, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2021, 6 years 3 months after primary completion. A results delay was requested in Feb 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lofexidine
USWM, LLC (dba US WorldMeds)